WHO Regional Office for Europe advice on the use of experimental medicines for the treatment of COVID-19 patients (09 April 2020)

This advice was developed to address questions from Member States regarding the use of experimental medicines in the treatment of COVID-19 patients. It summarizes current WHO recommendations for the treatment of COVID-19 patients, information on the ethical and legal requirements for the use of experimental medicines in clinical trials (the WHO SOLIDARITY trial or other Randomized Control Trials (RCT)) as well as donated medicines, and the possible impact on global supplies of essential medicines for the treatment of non-COIVD-19 patients where these drugs are included in COVID-19 clinical trials.